AcelRx Pharmaceuticals Inc
NASDAQ:ACRX
AcelRx Pharmaceuticals Inc
Cash from Financing Activities
AcelRx Pharmaceuticals Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
AcelRx Pharmaceuticals Inc
NASDAQ:ACRX
|
Cash from Financing Activities
$8.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-20%
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$15.8B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-7%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$8.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
$26.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$4.8B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
-5%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$3.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is AcelRx Pharmaceuticals Inc's Cash from Financing Activities?
Cash from Financing Activities
8.8m
USD
Based on the financial report for Sep 30, 2023, AcelRx Pharmaceuticals Inc's Cash from Financing Activities amounts to 8.8m USD.
What is AcelRx Pharmaceuticals Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
-20%
Over the last year, the Cash from Financing Activities growth was 46%. The average annual Cash from Financing Activities growth rates for AcelRx Pharmaceuticals Inc have been -1% over the past three years , -17% over the past five years , and -20% over the past ten years .